首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1812416

他汀类药物市场按产品类型、药物类别、适应症、他汀类药物类型、剂型、强度、销售管道、年龄层、性别、分销管道和地区划分

Statins Market, By Product Type, By Drug Class, By Indication Prevention of Myocardial, By Type of Statin, By Formulation, By Strength, By Sales Channel, By Age Group, By Gender, By Distribution Channel, By Geography

出版日期: 2025年08月01日 | 出版商:

Coherent Market Insights | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计 2025 年他汀类药物市场价值将达到 172.5 亿美元，到 2032 年预计将达到 249.6 亿美元，2025 年至 2032 年的复合年增长率为 5.42%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	172.5亿美元
效能数据	2020年至2024年	预测期	2020年至2024年
预测期：2025-2032年复合年增长率：	5.42%	2032年的价值预测	249.6亿美元

全球他汀类药物市场是心血管领域最重要的医药区隔之一，涵盖了彻底改变全球心臟病治疗和预防的降胆固醇药物。他汀类药物的科学名称为HMG-CoA还原酶抑制剂，透过抑制肝臟中负责胆固醇合成的酵素发挥作用，有效降低低密度脂蛋白(LDL)胆固醇水平，并最大限度地降低心血管风险因素。受高胆固醇症盛行率上升、心血管疾病意识增强以及全球老龄人口增长等因素的影响，该市场正在经历显着增长。

市面上提供各式各样的他汀类药物，包括Atorvastatin、Simvastatin、rosuvastatin他汀、普伐他汀和洛伐他汀，并提供多种剂型和规格，以满足不同患者的需求。心血管疾病仍是全球主要死因，他汀类药物已成为第一级和第二级预防策略的基石，大量临床证据证明其在减少重大不利事件的有效性。市场格局以品牌药和非专利药并存为特征，专利到期对定价动态产生重大影响，同时也提高了全球不同经济地区患者的用药可及性。

市场动态

全球他汀类药物市场受到多种强劲驱动因素的支撑。心血管疾病和高胆固醇血症盛行率的上升，尤其是在已开发国家和开发中国家久坐不动的生活方式、不健康的饮食习惯和肥胖率持续上升的背景下，是关键的成长催化剂。老年人口的成长，本身就具有较高的高胆固醇症风险，这催生了对降胆固醇疗法的持续需求，而医疗併发症的增加和保险覆盖范围的扩大也提高了市场可及性。预防保健意识的增强和定期胆固醇筛检计画的实施，使得人们能够更早诊断和开始治疗，从而进一步扩大了需要他汀类药物治疗的患者群体。

然而，市场面临许多限制因素，包括主要品牌他汀类药物专利到期后学名药的广泛供应，这导致价格竞争加剧，製药公司的利润率下降。对他汀类药物相关副作用（例如肌肉相关症状、肝酵素升高和潜在的糖尿病风险）的安全性担忧，导致一些医生和患者犹豫不决，从而影响了处方模式。此外，包括PCSK9抑制剂和新型调脂药物在内的替代降胆固醇疗法的出现，对传统的他汀类药物治疗构成了竞争挑战。监管的复杂性以及新剂型和新适应症的严格核准流程，为市场准入和创新设置了障碍。儘管如此，透过开发能够增强疗效并减少副作用的联合治疗、进入医疗基础设施日益完善的新兴市场以及探索他汀类药物在胆固醇管理之外的新应用（例如抑制炎症和神经保护），治疗领域和市场潜力仍有巨大的扩展潜力。

本次调查的主要特点

本报告对全球他汀类药物市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
它还强调了各个领域的潜在商机，并解释了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
该报告根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，概述了全球他汀类药物市场的主要企业。
本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
全球他汀类药物市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
透过用于分析全球他汀类药物市场的各种策略矩阵，相关人员将更容易做出决策。

预防心肌梗塞
中风预防
预防第2型糖尿病相关的心肌梗塞和中风
降低冠状动脉疾病的风险
原发性高血脂症的治疗
混合型血脂异常的治疗
高三酸甘油脂血症和原发性异常β脂蛋白血症
纯合子遗传性高胆固醇症（HoFH）的治疗
杂合子遗传性高胆固醇症（HeFH）（儿童）的治疗

7. 2020-2032 年全球他汀类药物市场（依他汀类药物类型）

天然他汀类药物
合成他汀类药物

8. 2020-2032 年全球他汀类药物市场（以剂型划分）

药片
胶囊

9. 全球他汀类药物市场（依实力划分），2020-2032 年

10mg
20mg
40mg
80mg

10. 全球他汀类药物市场依销售管道，2020-2032

处方
OTC

第 11 章。 2020-2032 年按年龄层分類的全球他汀类药物市场

孩子们
成人
老年人

第 12 章。 2020-2032 年全球他汀类药物市场（依性别）

男性
女士

13. 2020-2032 年全球他汀类药物市场（依通路）

医院药房
零售药局
网路药局

第 14 章。 2020-2032 年按地区分列的全球他汀类药物市场

北美洲
拉丁美洲
欧洲
亚太地区
中东
非洲

第十五章竞争格局

Pfizer Inc.
AstraZeneca
Merck & Co.
Novartis AG
Medicure Inc.
Teva Pharmaceutical
Mylan NV
Sun Pharmaceutical
Aurobindo Pharma
Reddy's Laboratories
Kowa Pharmaceuticals
Other Prominent Players

第 16 章分析师建议

机会
分析师观点
Coherent Opportunity Map

第十七章参考文献与调查方法

参考
调查方法
关于出版商

简介目录

Product Code: CMI8360

Statins Market is estimated to be valued at USD 17.25 Bn in 2025 and is expected to reach USD 24.96 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.42% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 17.25 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.42%	2032 Value Projection:	USD 24.96 Bn

The global statins market represents one of the most significant pharmaceutical segments in cardiovascular therapeutics, encompassing cholesterol-lowering medications that have revolutionized the treatment and prevention of heart disease worldwide. Statins, scientifically known as HMG-CoA reductase inhibitors, function by blocking the enzyme responsible for cholesterol synthesis in the liver, effectively reducing low-density lipoprotein (LDL) cholesterol levels and minimizing cardiovascular risk factors. This market has experienced substantial growth driven by the increasing prevalence of hypercholesterolemia, rising awareness of cardiovascular diseases, and expanding geriatric population globally.

The market encompasses various statin formulations including atorvastatin, simvastatin, rosuvastatin, pravastatin, and lovastatin, available in multiple dosage forms and strengths to cater to diverse patient needs. With cardiovascular diseases remaining the leading cause of mortality worldwide, statins have become cornerstone medications in both primary and secondary prevention strategies, supported by extensive clinical evidence demonstrating their efficacy in reducing major adverse cardiovascular events. The market landscape is characterized by the presence of both branded and generic formulations, with patent expirations having significantly impacted pricing dynamics while simultaneously improving accessibility for patients across different economic segments globally.

Market Dynamics

The global statins market is propelled by several compelling drivers, with the escalating prevalence of cardiovascular diseases and hypercholesterolemia serving as primary growth catalysts, particularly as sedentary lifestyles, unhealthy dietary patterns, and obesity rates continue to rise across developed and developing nations. The expanding geriatric population, who are inherently at higher risk for cardiovascular complications, creates sustained demand for cholesterol-lowering therapies, while increasing healthcare expenditure and improved insurance coverage enhance market accessibility. Growing awareness about preventive healthcare measures and routine cholesterol screening programs have led to earlier diagnosis and treatment initiation, further expanding the patient pool requiring statin therapy.

However, the market faces significant restraints including the widespread availability of generic alternatives following patent expirations of major branded statins, which has intensified price competition and compressed profit margins for pharmaceutical companies. Safety concerns related to statin-associated adverse effects such as muscle-related symptoms, liver enzyme elevations, and potential diabetes risk have created hesitancy among some physicians and patients, impacting prescription patterns. Additionally, the emergence of alternative cholesterol-lowering therapies, including PCSK9 inhibitors and newer lipid-modifying agents, poses competitive challenges to traditional statin therapy. Regulatory complexities and stringent approval processes for new formulations or indications create barriers to market entry and innovation. Nevertheless, substantial opportunities exist through the development of combination therapies that enhance efficacy while potentially reducing side effects, expansion into emerging markets with growing healthcare infrastructure, and the exploration of novel statin applications beyond cholesterol management, including potential benefits in inflammation reduction and neuroprotection, which could significantly broaden the therapeutic scope and market potential.

Key Features of the Study

This report provides in-depth analysis of the global statins market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global statins market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Pfizer Inc, AstraZeneca, Merck & Co, Novartis AG, Medicure Inc., Teva Pharmaceutical, Mylan NV, Sun Pharmaceutical, Aurobindo Pharma, Dr. Reddy's Laboratories, Kowa Pharmaceuticals, and other prominent players.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global statins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global statins market.

Market Segmentation

Product Type Insights (Revenue, USD Bn, 2020 - 2032)
- Generic Drugs
- Branded Drugs
Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Atorvastatin
- Fluvastatin
- Lovastatin
- Pravastatin
- Rosuvastatin
- Simvastatin
- Pitavastatin
Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Prevention of Myocardial Infarction
- Stroke Prevention
- Type 2 Diabetes-related MI and Stroke Prevention
- Coronary Heart Disease Risk Reduction
- Primary Hyperlipidemia Treatment
- Mixed Dyslipidemia Treatment
- Hypertriglyceridemia and Primary Dysbetalipoproteinemia
- Homozygous Familial Hypercholesterolemia (HoFH) Treatment
- Heterozygous Familial Hypercholesterolemia (HeFH) Treatment (Pediatric)
Type Of Statin Insights (Revenue, USD Bn, 2020 - 2032)
- Natural Statins
- Synthetic Statins
Formulation Insights (Revenue, USD Bn, 2020 - 2032)
- Tablets
- Capsules
Strength Insights (Revenue, USD Bn, 2020 - 2032)
- 10 mg
- 20 mg
- 40 mg
- 80 mg
Sales Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Prescription
- Over-the-Counter
Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
- Geriatric
Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Pfizer Inc.
- AstraZeneca
- Merck & Co
- Novartis AG
- Medicure Inc.
- Teva Pharmaceutical
- Mylan NV
- Sun Pharmaceutical
- Aurobindo Pharma
- Reddy's Laboratories
- Kowa Pharmaceuticals
- Other Prominent Players

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Statins Market, By Product Type
- Global Statins Market, By Drug Class
- Global Statins Market, By Indication
- Global Statins Market, By Type of Statin
- Global Statins Market, By Formulation
- Global Statins Market, By Strength
- Global Statins Market, By Sales Channel
- Global Statins Market, By Age Group
- Global Statins Market, By Gender
- Global Statins Market, By Distribution Channel
- Global Statins Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Statins Market, By Product Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Generic Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Branded Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Statins Market, By Drug Class, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Atorvastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Fluvastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Lovastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Pravastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Rosuvastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Simvastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Pitavastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Statins Market, By Indication, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Prevention of Myocardial Infarction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Stroke Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Type 2 Diabetes-related MI and Stroke Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Coronary Heart Disease Risk Reduction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Primary Hyperlipidemia Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Mixed Dyslipidemia Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Hypertriglyceridemia and Primary Dysbetalipoproteinemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Homozygous Familial Hypercholesterolemia (HoFH) Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Heterozygous Familial Hypercholesterolemia (HeFH) Treatment (Pediatric)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Statins Market, By Type of Statin, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Natural Statins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Synthetic Statins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Statins Market, By Formulation, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Statins Market, By Strength, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
10 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
20 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
40 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
80 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Statins Market, By Sales Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Prescription
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Over-the-Counter
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Statins Market, By Age Group, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

12. Global Statins Market, By Gender, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

13. Global Statins Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

14. Global Statins Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

15. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Medicure Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Mylan NV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sun Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Aurobindo Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Kowa Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Other Prominent Players
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

16. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

17. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格